Outcomes To investigate the long-term clinical and economic outcomes of various anti-diabetic treatments, researchers utilized the CORE diabetes (Center for Outcomes and Resource Evaluation) model, which simulates morbidity, mortality, and associated healthcare costs based on epidemiological data from extended clinical trials (16)(17)
Who Should Avoid IGF-1 Peptides
Another key driver is the diversification of therapeutic area, i.e., obesity and management of cardio metabolic risk to expand market opportunity
doi: 10.1111/dom.15184 Retrieved from Rosenstock, J., Hsia, S., Nevarez Ruiz, L., et al
This process is especially common with GLP-1 medications like Wegovy, Zepbound, and Ozempic, due to their high cost and increasing demand
My take on Danone launching this so closely behind the shelf stable protein shake that sit in the Nutritional section and are 12 oz is they see the GLP-1 segment as a bullseye, and I think thats why the CEO said theyve got a wait and see approach with the shake rollout: We want to validate repeat purchase before committing to national rollout I'd rather spend a few more weeks scaling up than go full and discover repeat isnt there. (dairyreporter.com) And that caution isnt without context Premier Protein and Core Power (Fairlife, Coca-Cola) currently dominate the nutritional shake category, logging 20% and 47% year-over-year growth, respectively
